Part 1: ABCDEF Bundle Overview & Pain Assessment and Management

The ABCDEF bundle framework for ICU liberation, comprehensive pain assessment tools (BPS, CPOT, NRS) with complete scoring tables, and evidence-based analgesic management including opioid dosing, non-opioid adjuncts, and multimodal protocols.

guidelinesMar 2026guidelines

The ABCDEF Bundle: A Framework for ICU Liberation

The ABCDEF bundle is an evidence-based, interprofessional approach to managing the interrelated domains of pain, sedation, delirium, immobility, and sleep in critically ill patients. Each element is complementary, and maximal benefit is achieved when all components are implemented together with high fidelity.1 2

Bundle Components

LetterDomainCore Intervention
AAssess, Prevent, and Manage PainRoutine pain assessment with validated tools; analgesia-first approach; multimodal strategies
BBoth Spontaneous Awakening Trials (SAT) and Spontaneous Breathing Trials (SBT)Daily paired SAT + SBT for ventilated patients when safety criteria are met
CChoice of Analgesia and SedationLight sedation targeting (RASS 0 to −2); preference for non-benzodiazepine agents; analgesia-based sedation
DDelirium: Assess, Prevent, and ManageRoutine delirium screening (CAM-ICU or ICDSC); non-pharmacologic prevention; treat underlying causes
EEarly Mobility and ExerciseProgressive mobilization beginning within 24–48 hours of ICU admission when hemodynamically stable
FFamily Engagement and EmpowermentActive family participation in care; structured communication; family presence at rounds and during procedures when appropriate

Evidence for the ABCDEF Bundle

A prospective cohort study of over 15,000 adults across 68 ICUs demonstrated dose-dependent benefits of ABCDEF bundle compliance.2 For each 10% increase in proportional bundle compliance:

  • Delirium: 15% lower odds of delirium the next day (adjusted OR 0.85, 95% CI 0.83–0.87)
  • Coma: 15% lower odds of coma the next day (adjusted OR 0.85, 95% CI 0.82–0.88)
  • Mechanical ventilation: 10% increase in the odds of being liberated from the ventilator within 3 days
  • ICU discharge: 8% higher odds of ICU discharge alive within 7 days
  • ICU readmission: 14% lower odds of ICU readmission
  • Mortality: 32% lower likelihood of death during the 7-day analysis period for complete (100%) versus partial (≤ 20%) compliance

Implementation Principles

  1. Interprofessional coordination — the bundle requires collaboration among physicians, nurses, respiratory therapists, pharmacists, physical/occupational therapists, and families
  2. Routine, protocolized assessment — use validated tools at regular intervals (every 2–4 hours and before/after interventions)
  3. Documentation and feedback — bundle compliance should be tracked, reported, and used for continuous quality improvement
  4. Culture change — successful implementation requires institutional commitment, education, and dedicated champions in each discipline3

Section A: Pain Assessment and Management

Prevalence and Impact of Pain in the ICU

Pain is reported by more than 50% of critically ill patients at rest and up to 80% during common ICU procedures (turning, tracheal suctioning, wound care, arterial line insertion, chest tube removal).4 5 Unrecognized and untreated pain causes:

  • Sympathetic activation (tachycardia, hypertension, increased myocardial oxygen demand)
  • Splinting and hypoventilation, increasing atelectasis risk
  • Agitation, self-removal of devices, and unplanned extubation
  • Sleep disruption and delirium
  • Immunosuppression and impaired wound healing
  • Post-traumatic stress disorder (PTSD) after ICU discharge

Key Recommendations for Pain Management

#RecommendationStrength
1Routine pain assessment is recommended for all ICU patients, performed at regular intervals and documentedStrong recommendation
2For patients able to self-report, the Numeric Rating Scale (NRS, 0–10) is the preferred pain assessment toolStrong recommendation
3For patients unable to self-report, behavioral pain scales — the Behavioral Pain Scale (BPS) or the Critical-Care Pain Observation Tool (CPOT) — are recommendedStrong recommendation
4Vital signs alone should NOT be used to assess pain, though they may serve as a cue to initiate further assessmentStrong recommendation
5An analgesia-first sedation approach is recommended, treating pain before administering sedative agentsConditional recommendation
6Multimodal analgesia (combining opioids with non-opioid adjuncts) is recommended to reduce total opioid requirementsConditional recommendation
7Pre-emptive analgesia should be administered before known painful proceduresConditional recommendation

Pain Assessment Tools

Numeric Rating Scale (NRS)

The NRS is the gold-standard self-report pain assessment tool for patients who can communicate. The patient rates pain intensity on a scale from 0 (no pain) to 10 (worst possible pain).4

NRS ScorePain SeveritySuggested Response
0No painNo intervention required
1–3Mild painNon-pharmacologic interventions; consider non-opioid analgesics
4–6Moderate painPharmacologic intervention indicated; reassess within 30–60 minutes
7–10Severe painUrgent pharmacologic intervention; reassess within 15–30 minutes

When to use the NRS: The patient must be alert (RASS ≥ −1), oriented, and able to understand and respond to the question. If unable to verbalize, the patient may point to a number on a visual scale.

Behavioral Pain Scale (BPS)

The BPS is a validated tool for assessing pain in sedated, mechanically ventilated patients who cannot self-report. It evaluates three behavioral domains. Total score ranges from 3 (no pain) to 12 (maximum pain). A score ≥ 5 indicates clinically significant pain requiring intervention.4 6

BPS — Complete Scoring Table

DomainDescriptionScore
Facial Expression
Relaxed1
Partially tightened (e.g., brow lowering)2
Fully tightened (e.g., eyelid closing)3
Grimacing (e.g., brow lowering, eyelid tightening, nose wrinkling, lip raise, mouth opening)4
Upper Limb Movements
No movement1
Partially bent2
Fully bent with finger flexion3
Permanently retracted (pulling on tube or lines)4
Compliance with Mechanical Ventilation
Tolerating movement1
Coughing but tolerating ventilation for most of the time2
Fighting ventilator3
Unable to control ventilation (requiring manual ventilation)4
BPS Total ScoreInterpretationAction
3No pain behaviors observedContinue monitoring every 2–4 hours
4Possible painReassess in 15 minutes; consider non-pharmacologic measures
5–6Clinically significant painAdminister analgesic; reassess in 30 minutes
7–9Moderate-to-severe painAdminister or escalate analgesic; reassess in 15–30 minutes
10–12Severe painUrgent analgesic administration; consider bolus opioid; reassess in 15 minutes

BPS for Non-Intubated Patients (BPS-NI): A modified version replaces the ventilator compliance domain with vocalization assessment:

Vocalization (BPS-NI)Score
No vocalization1
Moaning (low-pitched, sustained sound)2
Crying out (high-pitched sound, sustained or intermittent)3
Screaming or verbal complaint of pain4

Critical-Care Pain Observation Tool (CPOT)

The CPOT evaluates four behavioral and one physiologic domain. Total score ranges from 0 (no pain) to 8 (maximum pain). A score ≥ 3 indicates clinically significant pain requiring intervention.4 7

CPOT — Complete Scoring Table

DomainDescriptionScore
Facial Expression
Relaxed, neutral — no muscular tension observed0
Tense — furrowing of brow, lowering of eyebrows, tightening of orbicularis oculi1
Grimacing — all of the above plus eyelids tightly closed, mouth opened, biting endotracheal tube2
Body Movements
Absence of movements or normal position — does not move at all (does not necessarily mean absence of pain) or normal position0
Protection — slow, cautious movements; touching or rubbing the pain site; seeking attention through movements1
Restlessness/agitation — pulling tube, attempting to sit up, moving limbs/thrashing, does not follow commands, striking at staff, trying to climb out of bed2
Compliance with Ventilator (Intubated) OR Vocalization (Non-Intubated)
Intubated:
Tolerating ventilator or movement — alarms not activated, easy ventilation0
Coughing but tolerating — alarms may be activated but stop spontaneously1
Fighting ventilator — asynchrony, blocking ventilation, alarms frequently activated2
Non-Intubated:
Talking in normal tone or no sound0
Sighing, moaning1
Crying out, sobbing2
Muscle Tension (evaluated by passive flexion and extension of the upper extremity)
Relaxed — no resistance to passive movements0
Tense, rigid — resistance to passive movements1
Very tense or rigid — strong resistance to passive movements or inability to complete them2
CPOT Total ScoreInterpretationAction
0No pain behaviors observedContinue routine monitoring every 2–4 hours
1–2Possible mild painReassess in 15 minutes; consider non-pharmacologic measures
3–4Clinically significant painAdminister analgesic; reassess within 30 minutes
5–6Moderate-to-severe painAdminister or escalate analgesic; reassess within 15–30 minutes
7–8Severe painUrgent analgesic administration; reassess within 15 minutes

Choosing Between BPS and CPOT

FeatureBPSCPOT
Score range3–120–8
Minimum score interpretation3 = no pain behaviors0 = no pain behaviors
Clinically significant pain threshold≥ 5≥ 3
Domains assessed3 (facial, limb movement, ventilator)4 (facial, body movement, ventilator/vocalization, muscle tension)
Can be used in non-intubated patientsYes (BPS-NI variant)Yes (vocalization replaces ventilator domain)
Validated populationsMedical, surgical, trauma ICU; post-operativeMedical, surgical, trauma ICU; post-operative; brain-injured
Sensitivity to pain interventionsGoodGood
Interrater reliability (kappa)0.67–0.830.52–0.88

Recommendation: Either BPS or CPOT may be used. The CPOT has a broader evidence base, includes muscle tension assessment, and has been validated in brain-injured patients. An institution should choose one tool and use it consistently.4

Pain Assessment Protocol

  1. Assess pain at least every 2 hours in all ICU patients and document
  2. Assess before and 15–30 minutes after any analgesic intervention
  3. Assess before, during, and after known painful procedures
  4. Use self-report (NRS) whenever possible — it is the most reliable measure
  5. Use BPS or CPOT for patients who cannot self-report
  6. Never rely on vital signs alone — tachycardia and hypertension have poor sensitivity and specificity for pain
  7. Consider proxy report (family members who know the patient’s typical pain behaviors) as a supplemental source
  8. Document and trend scores to evaluate treatment effectiveness

Pharmacologic Pain Management

Analgesia-First Approach

The 2018 guidelines recommend an analgesia-first (also called “analgosedation”) approach: treat pain before reaching for sedative agents. Many patients who appear agitated are actually in pain; treating the pain resolves the agitation without additional sedation. This approach is associated with:4 8

  • Reduced total sedative use
  • Shorter duration of mechanical ventilation
  • Shorter ICU length of stay
  • Lower incidence of delirium

Opioid Analgesics

Opioids remain the cornerstone of ICU pain management for moderate-to-severe pain, particularly pain associated with mechanical ventilation, surgical wounds, and invasive procedures. Intravenous administration is preferred for predictable pharmacokinetics.4 9

IV Opioid Dosing — Complete Reference Table

AgentIV Bolus DoseOnsetPeakDurationContinuous InfusionKey Considerations
Fentanyl25–100 mcg q 0.5–1 h1–2 min3–5 min0.5–1 h25–200 mcg/h (0.7–10 mcg/kg/h)No active metabolites; preferred in renal/hepatic impairment; lipophilic — accumulates with prolonged use; chest wall rigidity at high doses (> 5 mcg/kg rapid bolus); no histamine release
Hydromorphone0.2–1 mg q 1–2 h5 min10–20 min2–4 h0.5–3 mg/h (7–15 mcg/kg/h)5–7× potency of morphine; minor active metabolite (hydromorphone-3-glucuronide — neuroexcitatory, accumulates in renal failure); less histamine release than morphine
Morphine2–5 mg q 1–2 h5–10 min15–30 min3–4 h2–30 mg/h (0.07–0.5 mg/kg/h)Active metabolite (morphine-6-glucuronide) accumulates in renal failure — prolonged sedation/respiratory depression; causes histamine release — avoid in hemodynamically unstable patients and bronchospasm; oldest, most studied agent
RemifentanilNot applicable (given only as infusion)1–3 min3–5 min3–10 min0.5–15 mcg/kg/h (starting 1.5 mcg/kg/h)Ultra-short acting; metabolized by nonspecific plasma and tissue esterases — organ-independent elimination; ideal for neurologic assessments requiring rapid wake-up; no accumulation; may cause acute opioid tolerance and hyperalgesia with prolonged use; abrupt discontinuation causes rapid withdrawal
Methadone5–10 mg q 8–12 h (loading)10–20 min60–120 min4–8 h (initial); 24–36 h (steady state)Not typically used as infusionLong, variable half-life (15–60 h); NMDA receptor antagonist properties — useful for neuropathic pain and opioid tolerance; QTc prolongation risk — monitor ECG; useful for opioid rotation in tolerant patients

Opioid Selection Algorithm

1. Is the patient hemodynamically unstable or in renal failure?
   → YES: Use fentanyl (no histamine release, no active metabolites in renal failure)
   → NO: Proceed to step 2

2. Are frequent neurologic assessments needed (e.g., TBI, post-neurosurgery)?
   → YES: Use remifentanil (ultra-short offset) or fentanyl (short offset)
   → NO: Proceed to step 3

3. Is the patient on prolonged opioid infusion with escalating requirements?
   → YES: Consider opioid rotation; add non-opioid adjuncts; consider methadone
   → NO: Proceed to step 4

4. Standard ICU patient requiring intermittent or continuous analgesia:
   → Fentanyl or hydromorphone preferred
   → Morphine acceptable if no renal impairment and hemodynamically stable

Opioid Equianalgesic Conversion Table (IV)

AgentIV Dose Equivalent to Morphine 10 mg IV
Fentanyl100 mcg
Hydromorphone1.5 mg
Morphine10 mg
RemifentanilNot applicable (ultra-short acting; not converted)
MethadoneConversion is complex and non-linear — consult pharmacy

Non-Opioid Analgesic Adjuncts

Multimodal analgesia — the combination of opioids with non-opioid agents targeting different pain pathways — reduces opioid consumption, opioid-related side effects, and may improve pain control. The following agents are recommended as adjuncts:4 9 10

IV Acetaminophen (Paracetamol)

ParameterDetails
MechanismCentrally acting; inhibits COX-3, serotonergic pathways, cannabinoid pathways
Dose1 g IV q 6 h (max 4 g/day); reduce to 500 mg q 6 h (max 2 g/day) if weight < 50 kg or hepatic impairment
Onset / Duration5–10 min / 4–6 h
EvidenceReduces opioid consumption by 20–30% in post-operative and medical ICU patients
PrecautionsContraindicated in severe hepatic impairment (ALT > 10× ULN); dose reduction if CrCl < 30 mL/min in some protocols; monitor LFTs

Ketorolac (NSAID)

ParameterDetails
MechanismNon-selective COX inhibitor; potent analgesic and anti-inflammatory
Dose15–30 mg IV q 6 h; max duration 5 days; use 15 mg if age ≥ 65, weight < 50 kg, or renal impairment
Onset / Duration10–30 min / 4–6 h
EvidenceReduces opioid requirements by 25–45% in surgical ICU populations
PrecautionsGI bleeding risk; renal impairment (avoid if CrCl < 30 mL/min); platelet dysfunction; cardiovascular risk with prolonged use; avoid in hypovolemia; avoid concurrent with other NSAIDs or corticosteroids; hold in active hemorrhage

Low-Dose Ketamine

ParameterDetails
MechanismNMDA receptor antagonist; provides analgesia, anti-hyperalgesia, and anti-inflammatory effects at sub-anesthetic doses
Analgesic dose (sub-dissociative)Bolus: 0.1–0.35 mg/kg IV; Infusion: 0.05–0.4 mg/kg/h (1–5 mcg/kg/min)
Onset / Duration30 seconds / 5–15 min (bolus); sustained during infusion
EvidenceReduces opioid consumption; may reduce opioid-induced hyperalgesia; useful in patients with chronic pain, opioid tolerance, or neuropathic pain; may reduce delirium incidence (emerging evidence)
PrecautionsPsychomimetic effects (vivid dreams, hallucinations) — generally minimal at analgesic doses; increases secretions; avoid in uncontrolled intracranial hypertension; historically cautioned in ICP concerns but recent evidence suggests safety when ventilation is controlled; increases heart rate and blood pressure — advantageous in hemodynamically unstable patients

Gabapentin / Pregabalin

ParameterGabapentinPregabalin
MechanismBinds alpha-2-delta subunit of voltage-gated calcium channels; modulates nociceptive signalingSame mechanism
Dose100–300 mg PO/NG q 8 h; titrate to 1,200 mg TID (max 3,600 mg/day)50–75 mg PO/NG q 12 h; titrate to 150–300 mg BID (max 600 mg/day)
Indication in ICUNeuropathic pain; opioid-sparing; may reduce post-surgical painSame indications; more predictable absorption
EvidenceConditional recommendation as adjunct to reduce opioid use in surgical ICU patientsSame; may reduce delirium in cardiac surgery patients
PrecautionsRenal dose adjustment required; sedation (additive with other CNS depressants); dizziness; requires enteral accessSame; lower dose needed than gabapentin for equivalent effect

Renal dose adjustments for gabapentin:

CrCl (mL/min)Maximum Daily Dose
≥ 603,600 mg (divided TID)
30–591,400 mg (divided BID)
15–29700 mg (once daily)
< 15 or HD300 mg (once daily; supplement 200–300 mg after each hemodialysis session)

Lidocaine IV Infusion

ParameterDetails
MechanismSodium channel blockade; systemic anti-inflammatory, anti-hyperalgesic
DoseLoading: 1–1.5 mg/kg IV over 10 min; Infusion: 1–2 mg/kg/h (max 3 mg/kg/h)
MonitoringContinuous cardiac monitoring; serum lidocaine levels q 12–24 h if infusion > 24 h; therapeutic analgesic range 1.5–5 mcg/mL; toxic > 5 mcg/mL
EvidenceReduces opioid consumption in post-operative patients; may reduce ileus duration; emerging evidence in burns and trauma
PrecautionsCardiac conduction abnormalities (AV block, bradycardia); seizures at toxic levels; hepatic metabolism (reduce dose in liver failure); avoid with other class I antiarrhythmics; monitor for perioral numbness, tinnitus, metallic taste (early toxicity signs)

Regional Anesthesia and Nerve Blocks in the ICU

Regional anesthesia provides targeted analgesia with minimal systemic effects and is increasingly used in critically ill patients.10 11

TechniquePrimary IndicationsConsiderations
Thoracic epiduralRib fractures (≥ 3), thoracotomy, upper abdominal surgeryImproved pulmonary mechanics, reduced opioid use; contraindicated with coagulopathy or hemodynamic instability requiring vasopressors; risk of epidural hematoma/abscess
Paravertebral blockRib fractures, thoracotomyAlternative to epidural; unilateral; fewer hemodynamic effects; can be performed in anticoagulated patients (with caution)
Erector spinae plane (ESP) blockRib fractures, thoracic surgery, abdominal surgeryFascial plane block — lower risk profile; can place catheter for continuous infusion; evidence growing
Transversus abdominis plane (TAP) blockAbdominal surgery, laparotomyProvides somatic analgesia to anterior abdominal wall; does not cover visceral pain
Femoral nerve / fascia iliaca blockHip fracture, femur fractureExcellent for lower extremity; reduces opioid requirements significantly
Serratus anterior plane blockChest wall trauma, chest tubes, thoracotomyProvides lateral chest wall analgesia
Scalp blockCraniotomy, TBI with external ventricular drainReduces systemic analgesic requirements

Anticoagulation and neuraxial procedures — safety guidelines:

AnticoagulantTime to Hold Before Neuraxial ProcedureResume After Procedure
Unfractionated heparin (SQ prophylactic)4–6 hours; check aPTT1 hour after
Unfractionated heparin (IV therapeutic)4–6 hours; aPTT must be normal1 hour after
Enoxaparin (prophylactic, 40 mg daily)12 hours4 hours after
Enoxaparin (therapeutic, 1 mg/kg BID)24 hours4 hours after
WarfarinINR ≤ 1.4After catheter removal
Direct oral anticoagulants (rivaroxaban, apixaban)72 hours (or 3 half-lives)6 hours after
Clopidogrel7 daysAfter catheter removal
Aspirin (alone)No contraindicationNo restriction

Multimodal Analgesia Protocol

The following protocol represents an evidence-based approach to multimodal, opioid-sparing analgesia in the ICU:4 9

Step 1 — Baseline for all patients (unless contraindicated):

  • IV acetaminophen 1 g q 6 h (scheduled)

Step 2 — Add based on pain type and severity:

  • Somatic/surgical pain: Add ketorolac 15–30 mg IV q 6 h (max 5 days) if no contraindication
  • Neuropathic component: Add gabapentin 100–300 mg PO q 8 h (titrate) or pregabalin 50–75 mg PO q 12 h
  • Opioid-tolerant/hyperalgesia: Add low-dose ketamine infusion 0.05–0.2 mg/kg/h

Step 3 — Opioid analgesia for breakthrough and moderate-to-severe pain:

  • Fentanyl 25–50 mcg IV q 30 min PRN, or
  • Hydromorphone 0.2–0.5 mg IV q 1–2 h PRN
  • If persistent moderate-severe pain: initiate continuous infusion (fentanyl 25–100 mcg/h or hydromorphone 0.5–2 mg/h)

Step 4 — Consider regional anesthesia:

  • Rib fractures: thoracic epidural, paravertebral, or ESP block
  • Abdominal surgery: epidural or TAP block
  • Extremity fractures: peripheral nerve block

Step 5 — Reassess and titrate:

  • Reassess pain (BPS/CPOT/NRS) q 2 h and after each intervention
  • Titrate to target: NRS ≤ 3, BPS < 5, CPOT < 3
  • Taper opioid infusions by 10–25% every 6–12 h as pain improves
  • Transition from IV to enteral analgesics when absorptive capacity returns

Procedural Pain Management

Common ICU procedures cause predictable, significant pain. Pre-emptive analgesia should be provided before procedures whenever possible.4 5

Pain Intensity of Common ICU Procedures

ProcedureAverage Pain Intensity (NRS 0–10)Category
Turning/repositioning4.9Moderate
Tracheal suctioning4.6Moderate
Wound drain removal5.2Moderate-Severe
Chest tube removal5.5Moderate-Severe
Arterial line insertion3.8Mild-Moderate
Central venous catheter insertion3.5Mild-Moderate
Wound care/dressing change5.1Moderate-Severe
Physical therapy/mobilization4.1Moderate
Femoral catheter removal4.2Moderate
Bronchoscopy3.9Mild-Moderate

Pre-Procedural Analgesia Protocol

Procedure Pain LevelRecommended Pre-TreatmentTiming
Mild (NRS < 4 expected)Acetaminophen 1 g IV; consider non-pharmacologic measures15–30 min before
Moderate (NRS 4–6 expected)Fentanyl 25–50 mcg IV OR hydromorphone 0.2–0.5 mg IV5–10 min before
Severe (NRS ≥ 7 expected)Fentanyl 50–100 mcg IV AND consider ketamine 0.1–0.35 mg/kg IV; local/regional anesthesia when feasible5–10 min before

Non-Pharmacologic Pain Interventions

Non-pharmacologic methods should be used alongside, not instead of, pharmacologic analgesia:4

InterventionEvidence LevelApplication
Repositioning and comfort measuresModerateProper body alignment; offloading pressure areas; pillow support
Cold therapy (cryotherapy)ModeratePost-operative incisions; musculoskeletal pain; 15–20 min application
Music therapyModerateCalming music via headphones during procedures and at rest; reduces anxiety and analgesic requirements
Relaxation / guided imageryLow-ModerateFor alert patients; reduces anxiety component of pain
MassageLowMay reduce pain and anxiety; limited evidence in ICU
Family presenceLowReduces anxiety and may reduce pain perception
Environmental modificationLow-ModerateNoise reduction; light dimming; minimizing unnecessary stimulation

References


  1. Marra A, Ely EW, Pandharipande PP, Patel MB. “The ABCDEF Bundle in Critical Care.” Crit Care Clin. 2017;33(2):225-243. DOI: 10.1016/j.ccc.2016.12.005 ↩︎

  2. Pun BT, Balas MC, Barnes-Daly MA, et al. “Caring for Critically Ill Patients with the ABCDEF Bundle: Results of the ICU Liberation Collaborative in Over 15,000 Adults.” Crit Care Med. 2019;47(1):3-14. DOI: 10.1097/CCM.0000000000003482 ↩︎ ↩︎

  3. Barnes-Daly MA, Phillips G, Ely EW. “Improving Hospital Survival and Reducing Brain Dysfunction at Seven California Community Hospitals: Implementing PAD Guidelines Via the ABCDEF Bundle in 6,064 Patients.” Crit Care Med. 2017;45(2):171-178. DOI: 10.1097/CCM.0000000000002149 ↩︎

  4. Devlin JW, Skrobik Y, Gélinas C, et al. “Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.” Crit Care Med. 2018;46(9):e825-e873. DOI: 10.1097/CCM.0000000000003299 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  5. Puntillo KA, Max A, Tiber R, et al. “Determinants of Procedural Pain Intensity in the Intensive Care Unit: The Europain Study.” Am J Respir Crit Care Med. 2014;189(1):39-47. DOI: 10.1164/rccm.201306-1174OC ↩︎ ↩︎

  6. Payen JF, Bru O, Bosson JL, et al. “Assessing Pain in Critically Ill Sedated Patients by Using a Behavioral Pain Scale.” Crit Care Med. 2001;29(12):2258-2263. DOI: 10.1097/00003246-200112000-00004 ↩︎

  7. Gélinas C, Fillion L, Puntillo KA, Viens C, Fortier M. “Validation of the Critical-Care Pain Observation Tool in Adult Patients.” Am J Crit Care. 2006;15(4):420-427. DOI: 10.4037/ajcc2006.15.4.420 ↩︎

  8. Strøm T, Martinussen T, Toft P. “A Protocol of No Sedation for Critically Ill Patients Receiving Mechanical Ventilation: A Randomised Trial.” Lancet. 2010;375(9713):475-480. DOI: 10.1016/S0140-6736(09)62072-9 ↩︎

  9. Barr J, Fraser GL, Puntillo K, et al. “Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit.” Crit Care Med. 2013;41(1):263-306. DOI: 10.1097/CCM.0b013e3182783b72 ↩︎ ↩︎ ↩︎

  10. Chou R, Gordon DB, de Leon-Casasola OA, et al. “Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists.” J Pain. 2016;17(2):131-157. DOI: 10.1016/j.jpain.2015.12.008 ↩︎ ↩︎

  11. Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. “Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).” Reg Anesth Pain Med. 2018;43(3):263-309. DOI: 10.1097/AAP.0000000000000763 ↩︎